Hepatorenal Syndrome – Causes, Symptoms and Treatment
Hepatorenal syndrome (HRS) is a severe form of kidney failure occurring in patients with advanced liver disease. It is caused by circulatory disturbances and is life-threatening without prompt treatment.
Wissenswertes über "Hepatorenal Syndrome"
Hepatorenal syndrome (HRS) is a severe form of kidney failure occurring in patients with advanced liver disease. It is caused by circulatory disturbances and is life-threatening without prompt treatment.
What is Hepatorenal Syndrome?
Hepatorenal syndrome (HRS) is a serious and potentially life-threatening complication of advanced liver disease, characterized by the rapid deterioration of kidney function. Despite structurally normal kidneys, the organs fail due to severely impaired blood circulation caused by the underlying liver condition. HRS most commonly affects patients with liver cirrhosis, severe alcoholic hepatitis, or acute liver failure and represents a medical emergency requiring immediate intervention.
Causes and Pathophysiology
HRS develops as a result of complex circulatory changes triggered by impaired liver function:
- Portal hypertension: Increased pressure in the portal venous system causes dilation of the splanchnic blood vessels in the abdominal cavity.
- Reduced effective circulating volume: Blood pools in the dilated abdominal vessels, leading to decreased perfusion of vital organs, including the kidneys.
- Activation of vasoconstrictors: In response, the body releases vasoconstrictive hormones such as renin, aldosterone, and noradrenaline, which further reduce renal blood flow.
- Triggering factors: Infections (especially spontaneous bacterial peritonitis), gastrointestinal bleeding, excessive diuretic use, or large-volume paracentesis without adequate albumin supplementation can precipitate HRS.
Types of Hepatorenal Syndrome
Current classifications distinguish two main types:
- HRS Type 1 (HRS-AKI): Rapid, acute kidney injury with a significant rise in serum creatinine within days. This type is particularly life-threatening and requires immediate intensive care.
- HRS Type 2 (HRS-CKD): A slower, chronic course with moderate kidney impairment, often associated with refractory ascites. The prognosis is somewhat better than Type 1, though still serious.
Symptoms
Symptoms of HRS are often non-specific and may overlap with signs of the underlying liver disease:
- Markedly reduced urine output (oliguria or anuria)
- Rising serum creatinine and blood urea nitrogen (BUN)
- Fluid retention (ascites, peripheral edema)
- Confusion and altered consciousness (hepatic encephalopathy)
- Jaundice (icterus)
- Low blood pressure and circulatory instability
Diagnosis
HRS is diagnosed based on clinical and laboratory criteria according to internationally recognized guidelines (e.g., from the International Ascites Club):
- Presence of cirrhosis or acute liver failure
- Rise in serum creatinine (typically above 1.5 mg/dL or an increase of more than 0.3 mg/dL within 48 hours)
- Exclusion of other causes of kidney failure (e.g., hypovolemia, shock, nephrotoxic drugs, structural kidney disease)
- No improvement in kidney function after volume expansion with albumin infusion
Additional investigations include urinalysis, renal ultrasound, and comprehensive blood tests.
Treatment
Treatment of HRS must be initiated promptly and aims to improve renal perfusion while stabilizing liver function:
Pharmacological Therapy
- Terlipressin (a vasopressin analogue) is the first-line treatment: it constricts the dilated splanchnic vessels, thereby improving kidney perfusion.
- Albumin infusions are given alongside to increase effective circulating volume.
- Where terlipressin is unavailable, noradrenaline or the combination of midodrine and octreotide may be used as alternatives.
Renal Replacement Therapy
In advanced kidney failure, temporary dialysis may be required as a bridge to liver transplantation.
Liver Transplantation
Liver transplantation is the only curative treatment. By addressing the underlying cause, it leads to full recovery of kidney function in most cases, provided no permanent kidney damage has occurred.
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
In selected cases, a TIPS procedure may be considered to reduce portal pressure and improve circulatory hemodynamics.
Prognosis
Without treatment, the prognosis of HRS is very poor. Type 1 HRS has a median survival of only a few weeks without therapy. However, with modern pharmacological treatment and timely liver transplantation, survival rates can be significantly improved. Early recognition and rapid initiation of treatment are critical to patient outcomes.
References
- European Association for the Study of the Liver (EASL) - Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 2018.
- Ginès P, Krag A, Abraldes JG, Solà E, Martin-Llahi M, Kamath PS - Liver cirrhosis. The Lancet, 2021.
- Nadim MK, Kellum JA, Forni L, et al. - Acute kidney injury in patients with cirrhosis: ADQI consensus recommendations. Gut, 2021.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categorySermorelin
Triptorelin
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Hepatorenal Syndrome + Hepato-renal Syndrome + HRS